Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
Praveen J Patel,1 Helen Devonport,2 Sobha Sivaprasad,1 Adam H Ross,3 Gavin Walters,4 Richard P Gale,5 Andrew J Lotery,6 Sajjad Mahmood,7 James S Talks,8 Jackie Napier9 1National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institut...
Guardado en:
Autores principales: | Patel PJ, Devonport H, Sivaprasad S, Ross AH, Walters G, Gale RP, Lotery AJ, Mahmood S, Talks JS, Napier J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1630e390b8cb4fc2b403a25fc6033d82 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
por: Khanani AM, et al.
Publicado: (2019) -
Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg JG
Publicado: (2019) -
Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
por: Jia-Kang Wang, et al.
Publicado: (2018) -
Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice
por: Campos Polo R, et al.
Publicado: (2018) -
Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration
por: Taipale C, et al.
Publicado: (2018)